Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2012

01-03-2012 | Original article

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma

Authors: Hyun-Il Cho, Esteban Celis

Published in: Cancer Immunology, Immunotherapy | Issue 3/2012

Login to get access

Abstract

Plasmid DNA vaccination is an attractive way to elicit T cell responses against infectious agents and tumor cells. DNA constructs can be designed to contain multiple T cell epitopes to generate a diverse immune response to incorporate numerous antigens and to reduce limitations due to MHC restriction into a single entity. We have prepared cDNA plasmid constructs containing several mouse T cell epitopes connected by either furin-sensitive or furin-resistant linkers and studied the effects of a cationic cell-penetrating sequence from HIV-tat. Significant CD8 T cell responses were obtained with multi-epitope DNA vaccines followed by in vivo electroporation regardless of the type of linker used and whether the construct had the HIV-tat sequence. The magnitude of immune responses was very similar to all CD8 T cell epitopes contained within each vaccine construct, indicating the absence of immunodominance. Incorporating a T helper epitope into the constructs increased the T cell responses. Prophylactic and therapeutic antitumor responses against B16 melanoma were obtained using a construct containing epitopes from melanosomal proteins, indicating that this vaccination was successful in generating responses to self-antigens that potentially may be subjected to immune tolerance. These findings are useful for designing DNA vaccines for a multitude of diseases where T lymphocytes play a protective or therapeutic role.
Literature
1.
go back to reference Bijker MS, Melief CJ, Offringa R, van der Burg SH (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6(4):591–603PubMedCrossRef Bijker MS, Melief CJ, Offringa R, van der Burg SH (2007) Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6(4):591–603PubMedCrossRef
2.
go back to reference Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6(5):404–414PubMedCrossRef Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6(5):404–414PubMedCrossRef
3.
go back to reference De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11(5–6):203–209PubMedCrossRef De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11(5–6):203–209PubMedCrossRef
4.
go back to reference Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69(23):9012–9019PubMedCrossRef Cho HI, Celis E (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69(23):9012–9019PubMedCrossRef
5.
go back to reference Assudani D, Cho HI, DeVito N, Bradley N, Celis E (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68(23):9892–9899PubMedCrossRef Assudani D, Cho HI, DeVito N, Bradley N, Celis E (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68(23):9892–9899PubMedCrossRef
6.
go back to reference Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326–1334PubMedCrossRef Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67(3):1326–1334PubMedCrossRef
7.
go back to reference Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63(12):3281–3288PubMed Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63(12):3281–3288PubMed
8.
go back to reference Itoh T, Celis E (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28(5):430–437PubMedCrossRef Itoh T, Celis E (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28(5):430–437PubMedCrossRef
9.
go back to reference Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immuno 172(7):4575–4582 Lu J, Higashimoto Y, Appella E, Celis E (2004) Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immuno 172(7):4575–4582
10.
go back to reference Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immuno 166(12):7063–7071 Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E (2001) TAP-independent presentation of CTL epitopes by Trojan antigens. J Immuno 166(12):7063–7071
11.
go back to reference Cho HI, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117:135–144PubMedCrossRef Cho HI, Lee YR, Celis E (2011) Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117:135–144PubMedCrossRef
12.
go back to reference Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D (1999) High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96(8):4262–4267PubMedCrossRef Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D (1999) High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96(8):4262–4267PubMedCrossRef
13.
go back to reference Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16(9):867–870PubMedCrossRef Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16(9):867–870PubMedCrossRef
14.
go back to reference Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immuno 174(10):6292–6298 Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J (2005) Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immuno 174(10):6292–6298
15.
go back to reference Gronevik E, Mathiesen I, Lomo T (2005) Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 7(9):1246–1254PubMedCrossRef Gronevik E, Mathiesen I, Lomo T (2005) Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 7(9):1246–1254PubMedCrossRef
18.
go back to reference Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW (2005) A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol Immunother 54(2):157–171PubMedCrossRef Doan T, Herd K, Ramshaw I, Thomson S, Tindle RW (2005) A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour. Cancer Immunol Immunother 54(2):157–171PubMedCrossRef
19.
go back to reference Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166(9):5366–5373PubMed Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166(9):5366–5373PubMed
20.
go back to reference Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19(32):4652–4660PubMedCrossRef Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A (2001) Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19(32):4652–4660PubMedCrossRef
21.
go back to reference Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A (1999) Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6):589–596PubMedCrossRef Hanke T, Neumann VC, Blanchard TJ, Sweeney P, Hill AV, Smith GL, McMichael A (1999) Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6):589–596PubMedCrossRef
22.
go back to reference Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 181(3):2124–2133PubMed Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A (2008) Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol 181(3):2124–2133PubMed
23.
go back to reference Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK (2009) Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 10(6):636–646PubMedCrossRef Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK (2009) Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 10(6):636–646PubMedCrossRef
Metadata
Title
Design of immunogenic and effective multi-epitope DNA vaccines for melanoma
Authors
Hyun-Il Cho
Esteban Celis
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1110-7

Other articles of this Issue 3/2012

Cancer Immunology, Immunotherapy 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine